Albendazole
₹2,500.00
Applications
Descriptions. Albendazole is used to treat neurocysticercosis, an infection of the nervous system caused by pork tapeworms. This medicine is also used to treat cystic hydatid disease of the liver, lung, and peritoneum, an infection caused by dog tapeworms.
Description
Albendazole is an FDA-approved medication for treating a variety of parasitic worm infections. Albendazole is an antihelminthic medication with numerous indications such as cystic hydatid disease of the liver, lung, and peritoneum resulting from the larval form of the dog tapeworm, Echinococcus granulosus.
Preparation
The process comprises a) thiocyanating 2-nitroaniline of formula VI with ammonium thiocyanated in presence of a halogen to obtain 2-nitro-4-thiocyanoaniline of formula V; b)propylating 2-nitro-4-thiocyanoaniline of formula V with propylbromide in presence of n-propanol and a base in absence of a phase transfer catalyst …
Chemical Properties
ALBENZA (albendazole) is an orally administered broad-spectrum anthelmintic. Chemically, it is methyl 5-(propylthio)-2-benzimidazolecarbamate. Its molecular formula is C12H15N3O2S. Its molecular weight is 265.34.
Definition
Albendazole is an anthelmintic drug used to treat parasitic infections caused by tapeworms and other parasites in humans and animals.
Description
Product Name | Albendazole |
Usage/Application | Pharma |
Country of Origin | Made in India |
Bioavailability | 5% |
Melting Point | 208 to 210 DegreeC |
CAS No | 54965-21-8 |
Packaging Size | As Per Requirement |
Our Export Location as a Albendazole Manufacturer, Supplier, Exporter, Stockist from India.
Afghanistan
Albania Algeria Andorra Angola Antigua and Barbuda Argentina Armenia Australia Austria Austrian Empire Azerbaijan Baden Bahamas Bahrain Bangladesh Barbados Bavaria Belarus Belgium Belize Benin (Dahomey) Bolivia Liberia Libya Liechtenstein Lithuania Luxembourg Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mecklenburg-Schwerin Mecklenburg-Strelitz Mexico Micronesia Moldova Monaco Mongolia Montenegro |
Bosnia and Herzegovina
Botswana Brazil Brunei Brunswick and Lüneburg Bulgaria Burkina Faso Burma Burundi Cabo Verde Cambodia Cameroon Canada Cayman Islands Central African Republic Central American Federation Chad Chile China Colombia Comoros Congo Free State Costa Rica Morocco Mozambique Namibia Nassau Nauru Nepal Netherlands New Zealand Nicaragua Niger Nigeria North German Confederation North German Union North Macedonia Norway Oldenburg Oman Orange Free State Pakistan Palau Panama Papal States |
Cote d’Ivoire Croatia Cuba Cyprus Czechia Czechoslovakia Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Duchy of Parma East Germany Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Eswatini Ethiopia Federal Government of Germany Fiji Papua New Guinea Paraguay Peru Philippines Piedmont-Sardinia Poland Portugal Qatar Republic of Genoa* Republic of Korea (South Korea) Republic of the Congo Romania Russia Rwanda Saint Kitts and Nevis Saint Lucia Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia |
Schaumburg-Lippe* Finland France Gabon Gambia Georgia Germany Ghana Grand Duchy of Tuscany Greece Grenada Guatemala Guinea Guinea-Bissau Guyana Haiti Hanover Hanseatic Republics Hawaii Hesse Holy See Honduras Hungary Iceland Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Sudan Spain Sri Lanka Sudan Suriname Sweden Switzerland Syria Tajikistan Tanzania Texas Thailand |
India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kingdom of Serbia/Yugoslavia Kiribati Korea Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Lew Chew (Loochoo) Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Tuvalu Two Sicilies* Uganda Ukraine Union of Soviet Socialist Republics* United Arab Emirates United Kingdom Uruguay Uzbekistan Vanuatu Venezuela Vietnam Württemberg* Yemen Zambia Zimbabwe |
Reviews
There are no reviews yet.